Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
Barry A SingerSibyl WrayMark GudesblattBarbara BumsteadTjalf ZiemssenAshley BonnellMatthew ScaramozzaSeth LevinMathura ShanmugasundaramHailu ChenJason P MendozaJames B LewinSai L ShankarPublished in: Neurology and therapy (2024)
ClinicalTrials.gov identifier NCT02634307.